The Effectiveness and Safety of Artificial Intelligence(AI)-Assisted Medical Treatment Decision Support System Compared to Conventional Care in HFrEF Patients

A Multicenter, Cluster-randomized, Controlled Study Evaluating the Effectiveness and Safety of Artificial Intelligence(AI)-Assisted Medical Treatment Decision Support System Compared to Conventional Care in HFrEF Patients

This clinical trial aims to find out if using an artificial intelligence (AI) decision support system can help doctors better manage medications for people with heart failure with reduced ejection fraction (HFrEF). The main goal is to see if this approach can lower the chance of patients being hospitalized for heart failure or dying from heart-related causes compared to standard care.

About 1,200 participants from 60 hospitals will take part in this study. The hospitals, not the individual patients, are randomly assigned to one of two groups:

AI-Guided Group: Doctors at these hospitals will receive medication recommendations from an AI system based on patient health data.

Standard Care Group: Doctors at these hospitals will manage medications as they normally would, without AI assistance.

All participants will have regular check-ups, both remotely every 30 days and in-person at 3, 6, and 12 months. The study will last about 12 months for each participant.

Inclusion Criteria:

1. Age ≥18 years old;
2. Patients diagnosed with HF in hospital and discharged on medical orders;
3. LVEF≤40% detected by echocardiography within 1 month before enrollment;
4. Signed informed consent is obtained.

Exclusion Criteria:

1. Patients who are unable or unsuitable for follow-up.
2. Patients with poor compliance, presenting a risk of switching study groups.